The application to the treatment of intraocular peroxisome proliferator-activatedreceptor gammma in patients with proliferative diabetic retinopathy.

Research Project

Project/Area Number	15K20265
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Ophthalmology
Research Institution	The University of Tokushima
Principal Investigator	KATOME Takashi 徳島大学, 病院, 講師 (50464342)
Project Period (FY)	2015-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Keywords	糖尿病網膜症 / VEGF / PPARγ / 血管新生
Outline of Final Research Achievements	The PPARγ concentrations in the aqueous humor and vitreous fluid were significantly higher in PDR patients than in controls (P<0.0005). There was a significant positive correlation between the PPARγ and VEGF concentrations (P<0.0005). The level of PPARγ increased as the clinical stage advanced. The expressions of the mRNA and protein of PPARγ were higher in the membranes of PDR than those of controls. Anti-VEGF therapy significantly reduced the VEGF concentration (P<0.0001) but not the PPARγ concentration. PPARγ may play an important role and a therapeutic target in the pathogenesis of PDR.